喘可治注射液联合布地奈德气雾剂治疗支气管哮喘急性发作患者的疗效及对患者炎性反应递质和肺功能的影响
|
摘要
目的:探讨喘可治注射液联合布地奈德气雾剂治疗支气管哮喘急性发作患者的疗效及对患者炎性反应递质和肺功能的影响。方法:选取2014年12月至2016年12月资阳市第一人民医院收治的哮喘急性发作患者84例,依据随机对照试验(单盲法)分为观察组和对照组,每组42例。观察组采用喘可治注射液联合布地奈德气雾剂治疗,对照组单纯采用布地奈德气雾剂治疗。2组疗程均为7d。比较2组疗效,主要症状体征评分、炎性反应递质及肺功能变化。结果:观察组总有效率(92. 86%)高于对照组(69. 05%),差异有统计学意义(P <0. 05);治疗后观察组咯痰、喘息、咳嗽、哮鸣音评分低于对照组,差异有统计学意义(P <0. 05);治疗后观察组白细胞介素-4(IL-4)、免疫球蛋白E(Ig E)水平低于对照组而干扰素-γ(IFN-γ)水平高于对照组,差异有统计学意义(P <0. 05);治疗后观察组FEV1占预计值、用力肺活量、呼气峰流量高于对照组,差异有统计学意义(P <0. 05)。结论:喘可治注射液联合布地奈德气雾剂治疗支气管哮喘急性发作患者疗效显著,且可改善患者炎性反应递质和肺功能。
Objective: To investigate the effects of Chuankezhi injection combined with budesonide aerosol in the treatment of acute attack of bronchial asthma and its influence on inflammatory mediators and pulmonary function. Methods: A total of 84 patients with acute attack of asthma in the First People's Hospital of Ziyang from December 2014 to December 2016 were divided into control group and observation group with 42 cases in each group according to random table method. The observation group was treated with Chuankezhi injection combined with budesonide aerosol. The control group was only treated with budesonide aerosol. The two groups were treated for 7 days. The two groups were compared with the main symptoms and signs score,inflammatory mediators and pulmonary function changes before and after treatment. Results: The total efficiency of the observation group (92. 86%) was higher than the control group (69. 05%) (P < 0. 05) with statistically significance. The phlegm,wheezing,cough,wheezing score in the observation group were lower than the control group (P < 0. 05). Interleukin-4 (IL-4) and immunoglobulin E (Ig E) levels after treatment in the observation group were lower than that of control group,but Interferon-γ (IFN-γ) level was higher than that of control group with statistically significance (P < 0. 05). The forced expiratory volume in one second (FEC1) for predicted value,forced vital capacity and peak expiratory flow in the observation after treatment was higher than that of control group (P < 0. 05).Conclusion: The treatment of acute attack of bronchial asthma with Chuankezhi injection combined with Budesonide Aerosol is effective,and it can improve the inflammatory mediators and lung function,which has important research significance.
Objective: To investigate the effects of Chuankezhi injection combined with budesonide aerosol in the treatment of acute attack of bronchial asthma and its influence on inflammatory mediators and pulmonary function. Methods: A total of 84 patients with acute attack of asthma in the First People's Hospital of Ziyang from December 2014 to December 2016 were divided into control group and observation group with 42 cases in each group according to random table method. The observation group was treated with Chuankezhi injection combined with budesonide aerosol. The control group was only treated with budesonide aerosol. The two groups were treated for 7 days. The two groups were compared with the main symptoms and signs score,inflammatory mediators and pulmonary function changes before and after treatment. Results: The total efficiency of the observation group (92. 86%) was higher than the control group (69. 05%) (P < 0. 05) with statistically significance. The phlegm,wheezing,cough,wheezing score in the observation group were lower than the control group (P < 0. 05). Interleukin-4 (IL-4) and immunoglobulin E (Ig E) levels after treatment in the observation group were lower than that of control group,but Interferon-γ (IFN-γ) level was higher than that of control group with statistically significance (P < 0. 05). The forced expiratory volume in one second (FEC1) for predicted value,forced vital capacity and peak expiratory flow in the observation after treatment was higher than that of control group (P < 0. 05).Conclusion: The treatment of acute attack of bronchial asthma with Chuankezhi injection combined with Budesonide Aerosol is effective,and it can improve the inflammatory mediators and lung function,which has important research significance.
引文
[1]Lieberman D,Lieberman D,Printz S,et al.Atypical pathogen infection in adults with acute exacerbation of bronchial asthma[J].Am JRespir Crit Care Med,2003,167(3):406-410.
[2]柳兴林.布地奈德联合沙丁胺醇雾化吸入治疗支气管哮喘急性发作的临床观察[J].医学理论与实践,2016,29(1):45-46.
[3]Kim S,Kim J,Park SY,et al.Effect of pregnancy in asthma on health care use and perinatal outcomes[J].J Allergy Clin Immunol,2015,136(5):1215-1223.e1-6.
[4]胡家荣.布地奈德联合特布他林雾化吸入治疗支气管哮喘急性发作疗效观察[J].吉林医学,2015,36(5):841-841.
[5]刘琳琳,杨巧玉,何青,等.完全控制支气管哮喘患者用药情况及其对哮喘急性发作的影响研究[J].中国全科医学,2015,4(31):3818-3821.
[6]杨巧云.沙丁胺醇、布地奈德联合治疗支气管哮喘急性发作疗效观察[J].中国继续医学教育,2016,8(10):161-162.
[7]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[J].中华结核和呼吸杂志,2008,31(3):177-185.
[8]中华人民共和国卫生部.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:53-60.
[9]李东升,李风森.哮喘病因及发病机制的研究进展[J].新疆中医药,2016,34(4):123-125.
[10]郭强,唐颖,闫百灵,等.血清肥大细胞羧肽酶与支气管哮喘的相关性研究[J].中国免疫学杂志,2017,33(11):1713-1715.
[11]钟远芹,蓝伟峰.布地奈德联合沙丁胺醇治疗支气管哮喘的效果及对患者TGF-β1、CRP水平和肺功能的影响[J].广东医学,2016,37(6):915-917.
[12]刘丽芬.雾化吸入布地奈德与沙丁胺醇治疗支气管哮喘急性发作对HMGB1的影响及治疗效果评价[J].临床肺科杂志,2016,21(5):805-808.
[13]杜忠健.中西医结合治疗哮喘急性发作期效果探讨[J].中医临床研究,2016,8(13):93-94.
[14]王腾云.探讨中西医结合治疗哮喘的效果[J].中西医结合心血管病杂志(连续型电子期刊),2016,4(18):164-165.
[15]蔡斌,周霖,单峥峥,等.喘可治注射液预防支气管哮喘急性发作的实验研究[J].上海医学,2003,26(1):62-63.
[16]方佳,王云,梁英英,等.喘可治注射液治疗支气管哮喘急性发作期患者临床观察[J].内科,2016,11(5):753-754,815.
[17]张晶,赖飞,梁小亮.支气管哮喘患者治疗前后血清IL-2、IL-4及外周全血T细胞亚群水平动态变化的研究[J].中国现代医学杂志,2016,26(19):69-74.
[18]吴晓蓉,汪俊,王红鸾,等.老年肺炎支原体感染合并支气管哮喘患者血清TNF-α,IL-4和Ig E的表达[J].中国老年学杂志,2015,35(22):6462-6464.
[19]邓赶飞,宋智心,杨蟠储.血清IL-17、IL-4、IFN-γ和IL-33与支气管哮喘的相关性研究[J].国际呼吸杂志,2016,36(21):1627-1630.
[20]姜明明,韩雪梅,于明涛.布地奈德对支气管哮喘患儿血清IL-4、CKLF-1和IFN-γ水平的影响[J].中国现代医生,2017,55(3):4-6.
[2]柳兴林.布地奈德联合沙丁胺醇雾化吸入治疗支气管哮喘急性发作的临床观察[J].医学理论与实践,2016,29(1):45-46.
[3]Kim S,Kim J,Park SY,et al.Effect of pregnancy in asthma on health care use and perinatal outcomes[J].J Allergy Clin Immunol,2015,136(5):1215-1223.e1-6.
[4]胡家荣.布地奈德联合特布他林雾化吸入治疗支气管哮喘急性发作疗效观察[J].吉林医学,2015,36(5):841-841.
[5]刘琳琳,杨巧玉,何青,等.完全控制支气管哮喘患者用药情况及其对哮喘急性发作的影响研究[J].中国全科医学,2015,4(31):3818-3821.
[6]杨巧云.沙丁胺醇、布地奈德联合治疗支气管哮喘急性发作疗效观察[J].中国继续医学教育,2016,8(10):161-162.
[7]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[J].中华结核和呼吸杂志,2008,31(3):177-185.
[8]中华人民共和国卫生部.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:53-60.
[9]李东升,李风森.哮喘病因及发病机制的研究进展[J].新疆中医药,2016,34(4):123-125.
[10]郭强,唐颖,闫百灵,等.血清肥大细胞羧肽酶与支气管哮喘的相关性研究[J].中国免疫学杂志,2017,33(11):1713-1715.
[11]钟远芹,蓝伟峰.布地奈德联合沙丁胺醇治疗支气管哮喘的效果及对患者TGF-β1、CRP水平和肺功能的影响[J].广东医学,2016,37(6):915-917.
[12]刘丽芬.雾化吸入布地奈德与沙丁胺醇治疗支气管哮喘急性发作对HMGB1的影响及治疗效果评价[J].临床肺科杂志,2016,21(5):805-808.
[13]杜忠健.中西医结合治疗哮喘急性发作期效果探讨[J].中医临床研究,2016,8(13):93-94.
[14]王腾云.探讨中西医结合治疗哮喘的效果[J].中西医结合心血管病杂志(连续型电子期刊),2016,4(18):164-165.
[15]蔡斌,周霖,单峥峥,等.喘可治注射液预防支气管哮喘急性发作的实验研究[J].上海医学,2003,26(1):62-63.
[16]方佳,王云,梁英英,等.喘可治注射液治疗支气管哮喘急性发作期患者临床观察[J].内科,2016,11(5):753-754,815.
[17]张晶,赖飞,梁小亮.支气管哮喘患者治疗前后血清IL-2、IL-4及外周全血T细胞亚群水平动态变化的研究[J].中国现代医学杂志,2016,26(19):69-74.
[18]吴晓蓉,汪俊,王红鸾,等.老年肺炎支原体感染合并支气管哮喘患者血清TNF-α,IL-4和Ig E的表达[J].中国老年学杂志,2015,35(22):6462-6464.
[19]邓赶飞,宋智心,杨蟠储.血清IL-17、IL-4、IFN-γ和IL-33与支气管哮喘的相关性研究[J].国际呼吸杂志,2016,36(21):1627-1630.
[20]姜明明,韩雪梅,于明涛.布地奈德对支气管哮喘患儿血清IL-4、CKLF-1和IFN-γ水平的影响[J].中国现代医生,2017,55(3):4-6.